Clinical Trials Browser

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT06762808 2025-08-15

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Phase 2 Withdrawn

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Phase 2 Withdrawn

CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Phase 2 Withdrawn

CNS

Glioblastoma

NCT06676917 2025-08-08

TUXEDO-5

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06498518 2025-07-11

PRIMUS006

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Phase 2 Withdrawn

Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

NCT04569461 2025-07-04

TALON

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05620914 2025-06-15

PARAMETer

Phase 2 Withdrawn

CNS

Brain Neoplasms

NCT06770257 2025-06-03

Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05840770 2025-05-26

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Phase 2 Withdrawn

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06361758 2025-05-23

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Phase 2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

NCT04685915 2025-05-22

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06895577 2025-05-21

Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

Phase 2 Withdrawn

Gastrointestinal

Rectal Neoplasms

NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Phase 2 Withdrawn

Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT04379492 2025-05-16

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Phase 2 Withdrawn

COVID-19

NCT03879811 2025-05-15

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Clinical Trials

HARMONY

ECLAT

MONAMI

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

INDIGO

OZM-034

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Study of ONC201 for Refractory Meningioma

PULSAR

BEMAFLOT

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

CaptAin

IMpALA

NeoSarc

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

PRISM

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology

REPRESENTATION

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

NANOPRO

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Neo-Kan

BIB 01

EMPIRE

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Abemaciclib + Pembrolizumab In Glioblastoma

TUXEDO-5

PRIMUS006

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

TALON

PARAMETer

Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer